Literature DB >> 15829061

A national survey amongst UK otolaryngologists regarding the treatment of Ménière's disease.

W K Smith1, V Sankar, A G Pfleiderer.   

Abstract

Since Dr Prosper Ménière described the vertiginous syndrome that now bears his name, a large variety of medical and surgical treatments have been introduced. To determine the way in which this condition is currently managed in the United Kingdom, a postal survey amongst consultant otolaryngologists was carried out. It revealed that 52 per cent were actively involved in the treatment of patients with Ménières disease using a wide range of medical and surgical therapies that have little or no evidence base. The survey found that 94 per cent of surgeons prescribe betahistine, 63 per cent diuretics and 71 per cent advise salt restriction to their patients, while 52 per cent of surgeons continue to recommend saccus decompression and 50 per cent are still inserting a grommet. However, two thirds of respondents now advocate the use of gentamicin therapy despite it only being introduced to this country just over 10 years ago. The results of this study and their relevance to the recommended present day management of Meniere's disease are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15829061     DOI: 10.1258/0022215053419871

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  16 in total

1.  Current treatment of vestibular, ocular motor disorders and nystagmus.

Authors:  Michael Strupp; Thomas Brandt
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 2.  [Surgical therapy in Menière's disease. Historical development and today's state of the art].

Authors:  G Baier; I Ott
Journal:  HNO       Date:  2008-05       Impact factor: 1.284

3.  Therapeutic strategies in the treatment of Menière's disease: the Italian experience.

Authors:  Nicola Quaranta; P Picciotti; G Porro; B Sterlicchio; G Danesi; P Petrone; Giacinto Asprella Libonati
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-04-11       Impact factor: 2.503

4.  An appraisal of the utility or futility of ENT consultant postal questionnaires.

Authors:  Stephen Ryan; J Saunders; E Clarke; J E Fenton
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-11-25       Impact factor: 2.503

5.  Histamine H4 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability.

Authors:  G Desmadryl; S Gaboyard-Niay; A Brugeaud; C Travo; A Broussy; A Saleur; J Dyhrfjeld-Johnsen; E Wersinger; C Chabbert
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

6.  Treatment of Menière's Disease.

Authors:  Jeffrey D Sharon; Carolina Trevino; Michael C Schubert; John P Carey
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

7.  Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study.

Authors:  Michael Strupp; Ludwig Kraus; Franz Schautzer; Dan Rujescu
Journal:  J Neurol       Date:  2018-03-12       Impact factor: 4.849

8.  Effect of standard-dose Betahistine on endolymphatic hydrops: an MRI pilot study.

Authors:  R Gürkov; W Flatz; D Keeser; M Strupp; B Ertl-Wagner; E Krause
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-04       Impact factor: 2.503

9.  Neuropharmacology of vestibular system disorders.

Authors:  Enrique Soto; Rosario Vega
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

10.  Menière's disease treated by grommet insertion.

Authors:  R G Kanegaonkar; A Najuko-Mafemera; R Hone; T Tikka
Journal:  Ann R Coll Surg Engl       Date:  2019-09-11       Impact factor: 1.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.